KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBIT: 2009-2025

Historic EBIT for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $882.0 million.

  • Teva Pharmaceutical Industries' EBIT rose 1829.41% to $882.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 279.05%. This contributed to the annual value of -$303.0 million for FY2024, which is 169.98% down from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' EBIT stood at $882.0 million, which was up 93.85% from $455.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' EBIT's 5-year high stood at $882.0 million during Q3 2025, with a 5-year trough of -$967.0 million in Q2 2022.
  • Moreover, its 3-year median value for EBIT was -$5.0 million (2024), whereas its average is $180.5 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' EBIT crashed by 1,576.92% in 2024 and then spiked by 9,200.00% in 2025.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' EBIT stood at $78.0 million in 2021, then slumped by 1,305.13% to -$940.0 million in 2022, then spiked by 180.43% to $756.0 million in 2023, then plummeted by 103.84% to -$29.0 million in 2024, then soared by 1,829.41% to $882.0 million in 2025.
  • Its EBIT was $882.0 million in Q3 2025, compared to $455.0 million in Q2 2025 and $519.0 million in Q1 2025.